Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083

Inclusion Criteria: * GHDA subjects as defined in the Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II * Fertile females must agree to use appropriate contraceptive methods and have a negative pregnancy test at inclusion * GH replacement therapy for more than 3 months * Body Mass Index (BMI, kg/m2) of 22.0 to 35.0 kg/m2, both inclusive Exclusion Criteria: * Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods * Malignant disease * Proliferative retinopathy judged by retina-photo within the last year - only with concomitant diabetes * Heart insufficiency, NYHA class greater than 2 * Subjects with diabetes with an HbA1C above 8.0% * Diabetic receiving insulin treatment * Stable pituitary replacement therapy for less than 3 months * Impaired liver function * Impaired kidney function